March 23rd 2023
In a recent study, uterine-sparing techniques led to reduced rates of recurrence and reintervention in patients with adenomyosis.
March 22nd 2023
March 22nd 2023
March 14th 2023
Patient, Provider, & Caregiver Connection: Individualizing Care in Multiple Sclerosis – Understanding Patient Challenges and the Role of Innovative Treatment
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
6th Annual Advanced Practice Collaborative
4th Annual International Congress on the Future of Women’s Health™
22nd Annual International Congress on the Future of Breast Cancer® East
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
Clinical Conversations With the Cancer Care Team: Discussing the Impact of Social Inequities on Treatment Outcomes in Triple-Negative Breast Cancer
Focusing on Fabry Disease in Females: Individualizing Diagnostic and Counseling Plans to Improve Long-Term Outcomes
FDA gives clearance and CLIA waiver to second generation sexual health testMarch 21st 2023
Visby Medical has announced its second generation point of care test for detecting sexually transmitted diseases in women has received 510(k) clearance and a CLIA waiver from the FDA.
Model estimates the optimal number of oocytes for ART treatmentMarch 15th 2023
A model to estimate the optimal number of oocytes to try to fertilize during assisted reproductive technology (ART) treatment predicted that 43.4% of oocyte retrievals were day 3 transfers; hence, exposing all oocytes to sperm is recommended.
The importance of menopause educationMarch 14th 2023
At the International Society for the Study of Women’s Sexual Health conference, held March 2 through 5 in St. Louis, Missouri, Michael Krychman, digital editor for Contemporary OB/GYN® talked with Barb Dehn, NP, from El Camino Women’s Medical Group in Mountain View, California, about the importance of helping professional women cope with menopause.
Covis withdraws Makena from the marketMarch 9th 2023
Covis, the manufacturer of the controversial preterm birth prevention drug Makena, has announced it will voluntarily withdraw the drug from the market after recommendations from the Center for Drug Evaluation and Research.